Selank

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analog of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide derived from IgG immunoglobulin. The modification from tuftsin involved extending the sequence with Pro-Gly-Pro to increase stability and bioavailability.

Selank is registered as a pharmaceutical drug in Russia and Ukraine for the treatment of generalized anxiety disorder and as an anxiolytic and nootropic agent. It is typically administered via nasal spray, which provides a convenient and potentially more CNS-targeted delivery route compared to injection.

Unlike most anxiolytic drugs (benzodiazepines, SSRIs, buspirone), Selank is claimed to provide anxiety relief without sedation, cognitive impairment, or significant withdrawal effects. This profile has made it attractive both in Russian clinical medicine and in the Western research/nootropic community. Its mechanism appears to involve the GABA system, serotonin pathways, and neurotrophin upregulation — though the full picture of its pharmacology continues to be studied.

Selank is not approved by the FDA and occupies a research chemical status in most Western countries.

Selank's anxiolytic and cognitive effects appear to arise from several mechanisms:

• GABA system modulation: Selank appears to enhance GABA(A) receptor function, potentially explaining its anxiolytic effects. Unlike benzodiazepines, which bind to a specific site on GABA(A) receptors and cause significant sedation, Selank's GABA modulation may be subtler and more selective, producing anxiolysis without marked sedation.
• Serotonergic effects: Selank influences serotonin uptake and metabolism in the CNS, affecting the 5-HT system that regulates mood, anxiety, and sleep. Inhibition of serotonin breakdown enzymes (MAO) may contribute to increased serotonergic tone.
• Enkephalin system: Selank has been shown to inhibit enkephalin-degrading enzymes, increasing the half-life of endogenous enkephalins (opioid peptides with mood-modulating and stress-protective effects).
• BDNF upregulation: Like Semax, Selank upregulates brain-derived neurotrophic factor (BDNF), contributing to synaptic plasticity and neuroprotective effects. This may account for the cognitive enhancement component of its activity.
• Dopamine modulation: Studies show Selank affects dopamine metabolism in specific brain regions, including the striatum and hippocampus, which may contribute to attention and motivation effects.
• Immunomodulatory effects: As a tuftsin analog, Selank retains some of tuftsin's immunomodulatory properties, influencing macrophage activation and cytokine profiles.

Research and clinical use of Selank supports several potential benefits:

• Anxiety reduction: Multiple Russian clinical studies and animal models demonstrate significant anxiolytic effects. Selank appears to reduce both trait anxiety (baseline anxiety levels) and state anxiety (situational anxiety responses).
• Non-sedating anxiolysis: A defining characteristic of Selank is its reported ability to reduce anxiety without the sedation, cognitive dulling, or motor impairment associated with benzodiazepines or even some SSRIs.
• Cognitive enhancement: Studies in both animals and healthy humans report improved attention, working memory, and information processing speed — suggesting nootropic activity independent of anxiety reduction.
• Stress resilience: Selank appears to improve the ability to cope with psychological stress, reducing stress-induced cognitive impairment and behavioral responses.
• Mood stabilization: Clinical reports describe mood-lifting effects that differ qualitatively from antidepressants, with a more immediate onset and no discontinuation syndrome.
• Immune support: As a tuftsin derivative, Selank may support immune function through macrophage activation and cytokine modulation, though this application is less studied than its neurological effects.
• Minimal tolerance/dependence: Unlike benzodiazepines, Selank does not appear to cause significant tolerance or physical dependence, based on clinical use in Russia and animal studies.

Selank has a favorable safety profile both in clinical studies and in anecdotal reports from the research community:

• Nasal irritation: The most commonly reported side effect; typically mild and often resolves with continued use
• Initial fatigue: Some users report temporary fatigue, particularly in the first few days of use
• Appetite changes: Reduced appetite has been reported in some cases
• Mild sedation: While much less sedating than benzodiazepines, some people report mild sedation, particularly at higher doses
• Rare allergic reactions: As with any peptide, allergic responses are theoretically possible

The absence of significant withdrawal syndrome, cognitive impairment, or addictive potential distinguishes Selank favorably from most conventional anxiolytic drugs. Long-term safety data from Russian clinical use suggests good tolerability. However, Western clinical trial data is lacking, and individual responses may vary significantly.

Disclaimer: Selank is not FDA-approved in the US. The following references Russian clinical protocols and research community conventions.

Administration details:

• Primary route: Intranasal spray; typical Russian pharmaceutical formulation is 0.15% solution
• Standard dose: 250–900 mcg per day (typically 2–3 sprays per nostril, 2–3 times daily with the 0.15% formulation)
• As-needed use: Selank is sometimes used acutely for stress situations rather than daily, owing to its rapid onset
• Cycle approach: Some protocols suggest 10–14 day courses with equivalent breaks to prevent any tolerance development, though this is not strongly supported by evidence
• N-Acetyl Selank Amidate: Modified versions with enhanced stability and potentially longer duration of action are available in the research community

Selank's research base is primarily Russian but encompasses both clinical and preclinical work:

• Anxiety disorder trials: Russian clinical trials have demonstrated statistically significant reductions in anxiety on standardized scales (Hamilton Anxiety Rating Scale) compared to placebo, with an onset within hours and sustained effects with continued use.
• Comparison to benzodiazepines: Studies have compared Selank to medazepam (a benzodiazepine) and demonstrated similar anxiolytic efficacy with substantially fewer cognitive side effects and no evidence of dependence development.
• Gene expression research: Russian research groups have profiled gene expression changes in brain regions after Selank administration, identifying effects on serotonin metabolism genes, GABA receptor subunit expression, and BDNF signaling pathways.
• Immune studies: Research has characterized Selank's effects on macrophage phagocytosis, IL-2 production, and other immune parameters, linking it to its tuftsin origins.

Selank's clinical evidence base from Russian trials is meaningful but limited by methodological standards below those expected by Western regulatory agencies. Independent replication of key findings in Western research settings would significantly strengthen confidence in the published effects.